Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 14, 2015; 21(38): 10874-10882
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10874
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10874
Table 1 Baseline characteristics of the patients n (%)
Variables | Total (n = 50) |
Age (yr)1 | 46.5 (22-74) |
Male | 37 (74) |
HBeAg-positive | 47 (94) |
Cirrhosis | 12 (24) |
Antiviral history before ETV (naïve/clevudine/LMV) | 2/2/46 (4/4/92) |
Duration of ETV (mo)1 | 24 (13-58) |
Serum ALT (IU/L)1 | 31 (5-1704) |
Serum total bilirubin level (mg/dL)1 | 0.84 (0.28-4.30) |
Serum albumin level (g/dL)1 | 4.2 (3.6-5.1) |
INR1 | 1.01 (0.87-1.30) |
Serum HBV DNA level (log10 IU/mL)1 | 5.53 (2.81-7.63) |
Duration of ADV combination therapy (mo)1 | 27 (12-45) |
Site of ETV-resistant mutations added on rtM204V/I | |
rt184 | 19 (38) |
rt202 | 22 (44) |
rt173 | 1 (2) |
rt169 + rt184 | 1 (2) |
rt184 + rt202 | 6 (12) |
rt184 + rt250 | 1 (2) |
Patients with elevated ALT level above ULN | 18 (36) |
Rescue therapy regimens [(ADV + LMV)/(ADV + ETV)] | 27/23 (54/46) |
Table 2 Comparison of clinical features between groups according to 1-year virologic response n (%)
Patients without VR (n = 32) | Patients with VR (n = 18) | P value | |
Age (yr)1 | 47 (22-70) | 42.5 (33-74) | 0.413 |
Male | 22 (68.8) | 15 (83.3) | 0.328 |
HBeAg-positive | 31 (96.9) | 16 (88.9) | 0.291 |
Cirrhosis | 8 (25) | 4 (22.2) | 1.000 |
Duration of ETV therapy (mo)1 | 24 (13-48) | 36 (17-58) | 0.003 |
Serum ALT level (IU/L)1 | 34.5 (12-918) | 29 (5-1704) | 0.210 |
Serum total bilirubin level (mg/dL)1 | 0.84 (0.31-1.99) | 0.79 (0.28-4.30) | 0.869 |
Serum albumin level (g/dL)1 | 4.2 (3.6-5.1) | 4.3 (3.6-4.9) | 0.691 |
INR1 | 1.01 (0.93-1.23) | 1.02 (0.87-1.30) | 0.848 |
Serum HBV DNA level (log10 IU/mL)1 | 6.16 (3.85-7.63) | 4.24 (2.81-7.08) | < 0.001 |
Site of ETV-resistant mutations | 0.441 | ||
rt184 | 12 (37.5) | 7 (38.9) | |
rt202 | 14 (43.8) | 8 (44.4) | |
rt173 | 0 (0) | 1 (5.6) | |
rt169 + rt184 | 0 (0) | 1 (5.6) | |
rt184 + rt202 | 5 (15.6) | 1 (5.6) | |
rt184 + rt250, | 1 (3.1) | 0 (0) | |
Presence of IVR-3 | 7 (21.9) | 17 (94.4) | < 0.001 |
Rescue therapy regimens (ADV/LMV vs ADV/ETV) | 19 vs 13 (59.4 vs 40.6) | 8 vs 10 (44.4 vs 55.6) | 0.382 |
Table 3 Multivariate analyses of clinical factors affecting one-year virologic response
RR | 95%CI | P value | |
Duration of ETV therapy (mo) | 1.039 | 0.936-1.153 | 0.473 |
Serum HBV DNA level (< 5.2 log10 IU/mL) | 7.614 | 1.160-49.986 | 0.034 |
Presence of IVR-3 | 24.862 | 2.398-257.781 | 0.007 |
Table 4 Univariate and multivariate analyses of factors affecting long-term virologic response
Univariate analysis | Multivariate analysis | |||||
RR | 95%CI | P value | RR | 95%CI | P value | |
Age (yr) | 1.011 | 0.973-1.050 | 0.586 | |||
Sex (male) | 1.156 | 0.488-2.740 | 0.741 | |||
HBeAg positivity (-) | 1.905 | 0.568-6.383 | 0.296 | |||
Disease status (LC) | 0.775 | 0.293-2.054 | 0.609 | |||
Duration of ETV (mo) | 1.077 | 1.036-1.119 | < 0.001 | 1.022 | 0.970-1.076 | 0.419 |
Serum ALT (IU/L) | 1.000 | 0.998-1.002 | 0.976 | |||
Serum total bilirubin level (mg/dL) | 1.405 | 0.774-2.550 | 0.264 | |||
Serum albumin level (g/dL) | 1.214 | 0.384-3.836 | 0.741 | |||
INR | 0.137 | 0.001-22.543 | 0.445 | |||
Serum HBV DNA level (< 5.2 log10 IU/mL) | 5.084 | 2.231-11.581 | < 0.001 | 2.870 | 1.049-7.854 | 0.040 |
Type of ETV-resistant mutation (rtT184 ) | 0.780 | 0.359-1.693 | 0.529 | |||
Presence of IVR-3 | 8.822 | 3.228-24.114 | < 0.001 | 4.417 | 1.402-13.918 | 0.011 |
Rescue therapy regimens (ADV/ETV) | 2.007 | 0.928-4.338 | 0.077 | 1.678 | 0.683-4.119 | 0.259 |
- Citation: Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882
- URL: https://www.wjgnet.com/1007-9327/full/v21/i38/10874.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i38.10874